|
|||||
|
|
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) |
|
| Authors: | John J. V. McMurray Milton Packer Akshay S. Desai Jim Gong Martin P. Lefkowitz Adel R. Rizkala Jean Rouleau Victor C. Shi Scott D. Solomon Karl Swedberg Michael R. Zile |
| Affiliation: | 1. BHF Cardiovascular Research Centre, University of Glasgow, , Glasgow, UK;2. University of Texas Southwestern Medical Center, , Dallas, TX, USA;3. Brigham and Women's Hospital, Cardiovascular Medicine, , MA, USA;4. Novartis Pharmaceutical Corporation, , East Hanover, NJ, USA;5. Université de Montréal, Institut de Cardiologie, , Montréal, Canada;6. University of Gothenburg, Cardiovascular Medicine Department, , Gothenburg, Sweden;7. The Medical University of South Carolina and RHJ Department of Veterans Administration Medical center, , Charleston, SC, USA |
| Abstract: | |
| Keywords: | Chronic heart failure Renin– angiotensin ACE inhibitor Angiotensin receptor blocker Natriuretic peptides Neprilysin Neutral endopeptidase Angiotensin receptor neprilysin inhibitor LCZ696 |